Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$30.50 USD
-0.04 (-0.13%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $30.51 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Xenon Pharmaceuticals Inc. has a market cap of $2.34B, which represents its share price of $30.54 multiplied by its outstanding shares number of 76.73M. As a mid-cap company, XENE's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
XENE 30.50 -0.04(-0.13%)
Will XENE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for XENE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for XENE
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus
XENE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High?
Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus
Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue?
Other News for XENE
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | XENE ...
Xenon Pharmaceuticals Inc (XENE) Announces Equity Inducement Grants | XENE stock news
BlackRock, Inc. Expands Stake in Xenon Pharmaceuticals Inc.
Citizens JMP pharmaceuticals analysts hold analyst/industry conference call
COMMODORE CAPITAL LP Acquires 1,175,000 Shares in Cidara Therapeutics Inc